Helix BioPharma Corp. saw a notable uptick in its stock price this week, driven by recent developments.
This week, Helix BioPharma Corp. (HBP.TO) experienced a price increase of 2.67%, closing at C$1.55 on Thursday. The stock has shown resilience, gaining 4.05% in just one day. Investors are paying close attention to the company as it continues to navigate its financial landscape and advance its product pipeline.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$70.27M
52W high
$3.00
52W low
$0.85
1W change
-3.16%
Beta
-0.14
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 171.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+171.7% Upside
Current Price
C$0.92
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
109.6%
Annualized
90-Day Vol
76.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.77
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.87 | C$0.59 – C$1.27 |
| 60 trading days | C$0.82 | C$0.48 – C$1.39 |
| 90 trading days | C$0.77 | C$0.40 – C$1.48 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Despite the challenges reflected in its year-to-date performance, Helix BioPharma's recent stock activity and financial maneuvers indicate a potential for recovery. Investors should monitor the company's ongoing developments as it seeks to advance its therapeutic candidates.
Stock Performance Overview
Helix BioPharma has shown a 1D increase of 4.05% and a 1M increase of 7.69%, but remains down 35.83% year-to-date.
Bull case
The positive outlook for Helix BioPharma is supported by an average analyst target of C$2.50, suggesting significant upside potential. The company's focus on advancing its pipeline candidates, including Tumor Defense Breaker™ L-DOS47, could lead to promising developments in the future.
Bear case
However, Helix BioPharma's market cap of approximately C$113 million and a year-to-date decline of 35.83% raise concerns about its financial stability and operational effectiveness. Investors should be cautious of the negative return on equity and ongoing operational losses.
Recent Price Action
Helix BioPharma Corp. has seen a positive week, with its stock price climbing 2.67% and closing at C$1.55. The stock gained 4.05% in a single day, indicating a potential shift in market sentiment. This comes amid a backdrop of ongoing interest in the company's therapeutic advancements.
Catalysts and Company News
Advertisement
While there have been no major announcements this week, Helix BioPharma has been actively managing its financial strategies. The company recently filed its interim financial statements for the three- and nine-month periods ending April 30, 2026, emphasizing its commitment to advancing its pipeline candidates, including Tumor Defense Breaker™ L-DOS47. This focus on development may support investor confidence.
Technical Picture
From a technical perspective, Helix BioPharma's last close at C$1.55 is above its 50-day moving average of C$1.48, reflecting a short-term bullish trend. However, it remains significantly below its 200-day moving average of C$1.91, suggesting longer-term challenges. The stock has a 52-week range of C$0.98 to C$5.40, currently trading at about 13% of that range. The stock's beta of -0.35 indicates lower volatility compared to the market, which may appeal to risk-averse investors.
Trading Volume Insights
Helix BioPharma recorded a trading volume of 1,850 shares, significantly higher than its 20-day average volume of 756 shares, indicating increased investor interest. The volume spike of 7.60 times the average suggests that the market is paying close attention to the stock, potentially driven by recent developments in the company's financial and operational strategies.
Price Action Summary
As of the latest close, Helix BioPharma shares are priced at C$1.55, reflecting a 1D increase of 4.05%. While the stock has shown some positive momentum recently, investors should remain cautious given the broader context of its year-to-date decline of 35.83%.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
